Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device

Inclusion Criteria

• •Signed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
• •The decision to initiate treatment with commercially available Fiasp® has been made by the patient and the treating physician before and independently from the decision to include the patient in this study
• •Male or female, age greater than or equal to 18 years at the time of signing informed consent
• •Diagnosed with T1DM at least 1 year prior to inclusion in the study
• •Stable treatment by MDI/CSII for at least 6 months prior to inclusion in the study. Stable treatment is defined as not changing the treatment method, with dose adjustments allowed
• •Regular (defined as usage on a monthly basis) user of Freestyle Libre® flash glucose monitoring for at least 6 months as the only continuous glucose monitoring (CGM) system actively used and availability of a full 2 weeks sensor download as "csv" file with 80% completeness of the data (if more sensor data are available, the 2 week data closest to baseline visit will be used)
• •Latest HbA1c value measured in the 3 months prior to inclusion in the study between 7.5-9.5%